Stocktube video
16/06/2014

ImmuPharma's Dimitriou explains opportunities for Nucant

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: IMM
Latest Price: 49.00p  (-2.00% Descending)
52-week High: 77.75p
52-week Low: 37.13p
Market Cap: 40.32M
1 year chart More charts
Deal IMM Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
ImmuPharma PLC
www.immupharma.com
Deal ImmuPharma PLC Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

ImmuPharma PLC is a pharmaceutical company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The...

Read more
Pdf

ImmuPharma sets sights on Lupuzor advancement and cancer programme in 2012

May 23 2012, 1:13pm He told shareholders 2011 had been an important year - where the firm had regained the rights to the lead compound Lupuzor, for the treatment of lupus

The main aim for drug discovery specialist ImmuPharma (LON:IMM) in 2012 are to advance its Lupuzor drug and its cancer treatment programme.

So said chief executive officer Dimitri Dimitriou at the firm's AGM earlier today.

He told shareholders 2011 had been an important year - where the firm had regained the rights to the lead compound Lupuzor, for the treatment of lupus.

Now the drug has approval from the US Food and Drug Administration to start a Phase III trial, along with obtaining fast track designation potentially shortening the approval time by a year. 

The company is also in detailed discussions with potential partners to re-licence the drug, while also exploring opportunities to retaining the rights until commercialisation, Dimitriou told shareholders.

"Our cancer programme, IPP-204106, has also made encouraging progress with promising early results in its Phase I/IIa trial," he said.  

"The trial is now completed and the data are being analysed and as previously announced 21 per cent of patients demonstrated disease stabilisation for more than 6 months. 

"The clinical development programme continues to be a key priority for ImmuPharma during 2012 with further clinical trials planned this year."

The CEO added: "Our key objectives for 2012 are to advance both LupuzorTM and our cancer programme and to continue to develop the rest of our asset base whilst continuing to carefully manage our cost base."

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.